Understanding nephrogenic systemic fibrosis

International Journal of Nephrology

Volumn 2012, Issue , 2012, Pages

  Chopra, Tushar ^a   Kandukurti, Kiran ^a   Shah, Silvi ^a   Ahmed, Raheel ^a   Panesar, Mandip ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870168503     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2012/912189     Document Type: Review

References (106)

1. Cowper S. E., Su L. D., Bhawan J., Robin H. S., LeBoit P. E., Nephrogenic fibrosing dermopathy. American Journal of Dermatopathology 2001 23 5 383 393 2-s2.0-0034790497 10.1097/00000372-200110000-00001 (Pubitemid 32938907)
2. Swartz R. D., Crofford L. J., Phan S. H., Ike R. W., Su L. D., Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. American Journal of Medicine 2003 114 7 563 572 2-s2.0-0037716844 10.1016/S0002-9343(03)00085-8 (Pubitemid 36577259)
3. Scheinfeld N., Nephrogenic fibrosing dermopathy: a comprehensive review for the dermatologist. American Journal of Clinical Dermatology 2006 7 4 237 247 2-s2.0-33747182205 10.2165/00128071-200607040-00005 (Pubitemid 44231919)
4. Cowper S. E., Rabach M., Girardi M., Clinical and histological findings in nephrogenic systemic fibrosis. European Journal of Radiology 2008 66 2 191 199 2-s2.0-43049113110 10.1016/j.ejrad.2008.01.016
5. Jain S. M., Wesson S., Hassanein A., Canova E., Hoy M., Fennell R. S., Dharnidharka V. R., Nephrogenic fibrosing dermopathy in pediatric patients. Pediatric Nephrology 2004 19 4 467 470 2-s2.0-1842788898 10.1007/s00467-003- 1380-1 (Pubitemid 38477417)
6. Jan F., Segal J. M., Dyer J., Leboit P., Siegfried E., Frieden I. J., Nephrogenic fibrosing dermopathy: two pediatric cases. Journal of Pediatrics 2003 143 5 678 681 2-s2.0-0345305361 10.1067/S0022-3476(03)00538-9 (Pubitemid 37452802)
7. Panda S., Bandyopadhyay D., Tarafder A., Nephrogenic fibrosing dermopathy: a series in a non-Western population. Journal of the American Academy of Dermatology 2006 54 1 155 159 2-s2.0-29244445466 10.1016/j.jaad.2005. 10.007 (Pubitemid 41832479)
8. Bangsgaard N., Marckmann P., Rossen K., Skov L., Nephrogenic systemic fibrosis: late skin manifestations. Archives of Dermatology 2009 145 2 183 187 2-s2.0-60349106558 10.1001/archdermatol.2008.551
9. Evenepoel P., Zeegers M., Segaert S., Claes K., Kuypers D., Maes B., Flamen P., Fransis S., Vanrenterghem Y., Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrology Dialysis Transplantation 2004 19 2 469 473 2-s2.0-1042292021 10.1093/ndt/gfg506 (Pubitemid 38196001)
10. Gibson S. E., Farver C. F., Prayson R. A., Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Archives of Pathology and Laboratory Medicine 2006 130 2 209 212 2-s2.0-32544437675 (Pubitemid 43237993)
11. Jiménez S. A., Artlett C. M., Sandorfi N., Derk C., Latinis K., Sawaya H., Haddad R., Shanahan J. C., Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β 1 expression in affected skin. Arthritis and Rheumatism 2004 50 8 2660 2666 2-s2.0-4043086401 10.1002/art.20362 (Pubitemid 39062729)
12. Levine J. M., Taylor R. A., Elman L. B., Bird S. J., Lavi E., Stolzenberg E. D., McGarvey M. L., Asbury A. K., Jimenez S. A., Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle and Nerve 2004 30 5 569 577 2-s2.0-7444248982 10.1002/mus.20153 (Pubitemid 39447280)
13. Girardi M., Kay J., Elston D. M., Leboit P. E., Abu-Alfa A., Cowper S. E., Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. Journal of the American Academy of Dermatology 2011 65 1095.e7 1106.e7
14. Cowper S. E., Nephrogenic fibrosing dermopathy: the first 6 years. Current Opinion in Rheumatology 2003 15 6 785 790 2-s2.0-0742287030 10.1097/00002281-200311000-00017 (Pubitemid 38156308)
15. Galan A., Cowper S. E., Bucala R., Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion in Rheumatology 2006 18 6 614 617 2-s2.0-33750221591 10.1097/01.bor.0000245725.94887.8d (Pubitemid 44607415)
16. Knopp E. A., Cowper S. E., Nephrogenic systemic fibrosis: early recognition and treatment. Seminars in Dialysis 2008 21 2 123 128 2-s2.0-40849104867 10.1111/j.1525-139X.2007.00399.x
17. Chiu H., Wells G., Carag H., Canova E., Firpi R. J., Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transplantation 2004 10 3 465 466 2-s2.0-1642366567 10.1002/lt.20068 (Pubitemid 38380326)
18. Ishibe S., Perazella M. A., Reilly R. F., Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Seminars in Dialysis 2003 16 3 276 280 2-s2.0-0141783887 10.1046/j.1525-139X.2003.16053.x (Pubitemid 37363230)
19. Chung H. J., Chung K. Y., Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. British Journal of Dermatology 2004 150 3 596 597 2-s2.0-1842506623 10.1111/j.1365-2133.2003.05795.x (Pubitemid 38446323)
20. Mackay-Wiggan J. M., Cohen D. J., Hardy M. A., Knobler E. H., Grossman M. E., Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). Journal of the American Academy of Dermatology 2003 48 1 55 60 2-s2.0-0037236042 10.1067/mjd.2003.78 (Pubitemid 36091534)
21. Tan A. W. H., Tan S. H., Lian T. Y., Ng S. K., A case of nephrogenic fibrosing dermopathy. Annals of the Academy of Medicine Singapore 2004 33 4 527 529 2-s2.0-4644338226 (Pubitemid 39280144)
22. Ting W. W., Stone M. S., Madison K. C., Kurtz K., Nephrogenic fibrosing dermopathy with systemic involvement. Archives of Dermatology 2003 139 7 903 906 2-s2.0-0042463648 10.1001/archderm.139.7.903 (Pubitemid 36898926)
23. Grobner T., Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrology Dialysis Transplantation 2006 21 4 1104 1108 2-s2.0-33645289942 10.1093/ndt/gfk062
24. Hubbard V., Davenport A., Jarmulowicz M., Rustin M., Scleromyxoedema-like changes in four renal dialysis patients. British Journal of Dermatology 2003 148 3 563 568 2-s2.0-0345700639 10.1046/j.1365-2133.2003.05181.x (Pubitemid 36461338)
25. Kafi R., Fisher G. J., Quan T., Shao Y., Wang R., Voorhees J. J., Kang S., UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Archives of Dermatology 2004 140 11 1322 1324 2-s2.0-8144230581 10.1001/archderm.140.11.1322 (Pubitemid 39473630)
26. Tran K. T., Prather H. B., Cockerell C. J., Jacobe H., UV-A1 therapy for nephrogenic systemic fibrosis. Archives of Dermatology 2009 145 1170 1174
27. Auron A., Shao L., Warady B. A., Nephrogenic fibrosing dermopathy in children. Pediatric Nephrology 2006 21 9 1307 1311 2-s2.0-33746962583 10.1007/s00467-006-0174-7 (Pubitemid 44203458)
28. Gilliet M., Cozzio A., Burg G., Nestle F. O., Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. British Journal of Dermatology 2005 152 3 531 536 2-s2.0-17444392456 10.1111/j.1365-2133.2005.06434.x (Pubitemid 40547128)
29. Kay J., High W. A., Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis and Rheumatism 2008 58 8 2543 2548 2-s2.0-49449100183 10.1002/art.23696
30. Robinson M. R., Routhouska S. B., Paspulati R. M., Korman N. J., Alefacept therapy for nephrogenic systemic fibrosis: a case series. Journal of Drugs in Dermatology 2011 10 922 924
31. Panesar M., Banerjee S., Barone G. W., Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clinical Transplantation 2008 22 6 803 808 2-s2.0-56349099743 10.1111/j.1399-0012.2008. 00886.x
32. Cuffy M. C., Singh M., Formica R., Simmons E., Abu Alfa A. K., Carlson K., Girardi M., Cowper S. E., Kulkarni S., Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2011 26 3 1099 1101 2-s2.0-79952132879 10.1093/ndt/gfq693
33. Leung N., Shaikh A., Cosio F. G., Griffin M. D., Textor S. C., Gloor J. M., Schwab T. R., Larson T. S., Dean P. G., Prieto M., Nyberg S. L., Stegall M. D., Lee C. U., Pittelkow M. R., The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. American Journal of Transplantation 2010 10 3 558 562 2-s2.0-76949099890 10.1111/j.1600-6143.2009. 02959.x
34. Agarwal R., Brunelli S. M., Williams K., Mitchell M. D., Feldman H. I., Umscheid C. A., Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation 2009 24 3 856 863 2-s2.0-60749120352 10.1093/ndt/gfn593
35. Nainani N., Panesar M., Nephrogenic systemic fibrosis. American Journal of Nephrology 2008 29 1 1 9 2-s2.0-47949132038 10.1159/000149628
36. Broome D. R., Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. European Journal of Radiology 2008 66 2 230 234 2-s2.0-43049114497 10.1016/j.ejrad.2008. 02.011
37. Fretellier N., Idée J. M., Guerret S., Hollenbeck C., Hartmann D., González W., Robic C., Port M., Corot C., Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Investigative Radiology 2011 46 2 85 93 2-s2.0-78751634456 10.1097/RLI.0b013e3181f54044
38. Fretellier N., Idée J. M., Dencausse A., Karroum O., Guerret S., Poveda N., Jestin G., Factor C., Raynal I., Zamia P., Port M., Corot C., Comparative in vivo dissociation of Gadolinium Chelates in renally impaired rats: a relaxometry study. Investigative Radiology 2011 46 5 292 300 2-s2.0-79954731621 10.1097/RLI.0b013e3182056ccf
39. Perazella M. A., Tissue deposition of gadolinium and development of NSF: a convergence of factors. Seminars in Dialysis 2008 21 2 150 154 2-s2.0-40849137746 10.1111/j.1525-139X.2007.00403.x
40. Gou B. D., Bian S., Zhang T. L., Wang K., Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. Toxicology In Vitro 2010 24 6 1743 1749 2-s2.0-77956172315 10.1016/j.tiv.2010.05.004
41. Del Galdo F., Wermuth P. J., Addya S., Fortina P., Jimenez S. A., NF κ B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases 2010 69 11 2024 2033 2-s2.0-78149473396 10.1136/ard.2010.134858
42. Del Galdo F., Wermuth P., Jimenez S. A., Activation of toll-like receptor pathways and induction of chemokine production in normal human macrophages by a gadolinium containing contrast agent: trigger event in the pathogenesis of nephrogenic systemic fibrosis? Arthritis and Rheumatism 2008 58 S831 S831
43. Wermuth P. J., Del Galdo F., Jiménez S. A., Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis and Rheumatism 2009 60 5 1508 1518 2-s2.0-66049130899 10.1002/art.24471
44. Steger-Hartmann T., Raschke M., Riefke B., Pietsch H., Sieber M. A., Walter J., The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Experimental and Toxicologic Pathology 2009 61 6 537 552 2-s2.0-66049095375 10.1016/j.etp.2008.11.004
45. Bucala R., Circulating fibrocytes: cellular basis for NSF. Journal of the American College of Radiology 2008 5 1 36 39 2-s2.0-37549054672 10.1016/j.jacr.2007.08.016
46. Swaminathan S., Shah S. V., New insights into nephrogenic systemic fibrosis. Journal of the American Society of Nephrology 2007 18 10 2636 2643 2-s2.0-34948888650 10.1681/ASN.2007060645 (Pubitemid 47531189)
47. Edward M., Quinn J. A., Mukherjee S., Jensen M. B. V., Jardine A. G., Mark P. B., Burden A. D., Gadodiamide contrast agent activates fibroblasts: a possible cause of nephrogenic systemic fibrosis. Journal of Pathology 2008 214 5 584 593 2-s2.0-41649098148 10.1002/path.2311 (Pubitemid 351482273)
48. Abraham J. L., Edward M., Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. American Journal of Roentgenology 2009 193 4, article W354 2-s2.0-70349678871 10.2214/AJR.08.2194
49. Edward M., Quinn J. A., Burden A. D., Newton B. B., Jardine A. G., Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 2010 256 3 735 743 2-s2.0-77956128433 10.1148/radiol.10091131
50. Bhagavathula N., Dasilva M., Aslam M. N., Dame M. K., Warner R. L., Xu Y., Fisher G. J., Johnson K. J., Swartz R., Varani J., Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Investigative Radiology 2009 44 8 433 439 2-s2.0-68449102455 10.1097/RLI.0b013e3181a4d7e9
51. Bhagavathula N., Dame M. K., DaSilva M., Jenkins W., Aslam M. N., Perone P., Varani J., Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Investigative Radiology 2010 45 12 769 777 2-s2.0-78650679876 10.1097/RLI.0b013e3181e943d2
52. Parsons A. C., Yosipovitch G., Sheehan D. J., Sangüeza O. P., Greenberg C. S., Sane D. C., Transglutaminases: the missing link in nephrogenic systemic fibrosis. American Journal of Dermatopathology 2007 29 433 436 (Pubitemid 47463850)
53. Kelly B., Petitt M., Sanchez R., Nephrogenic systemic fibrosis is associated with transforming growth factor β and Smad without evidence of renin-angiotensin system involvement. Journal of the American Academy of Dermatology 2008 58 6 1025 1030 2-s2.0-43249125755 10.1016/j.jaad.2008.02.038 (Pubitemid 351657614)
54. Schieren G., Gambichler T., Skrygan M., Burkert B., Altmeyer P., Rump L. C., Kreuter A., Balance of profibrotic and antifibroting signaling in nephrogenic systemic fibrosis skin lesions. American Journal of Kidney Diseases 2010 55 6 1040 1049 2-s2.0-77952552868 10.1053/j.ajkd.2010.01.021
55. Lim D., Phan T. T., Yip G. W., Bay B. H., Up-regulation of metallothionein isoforms in keloid keratinocytes. International Journal of Molecular Medicine 2006 17 2 385 389 2-s2.0-33644851283
56. Gupta A., Shamseddin M. K., Khaira A., Pathomechanisms of nephrogenic systemic fibrosis: new insights. Clinical and Experimental Dermatology 2011 36 7 763 768
57. Kelly B. C., Markle L. S., Vickers J. L., Petitt M. S., Raimer S. S., McNeese C., The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2010 63 483 489
58. Perone P. A., Weber S. L., Dasilva M., Paruchuri T., Bhagavathula N., Aslam M. N., Dame M. K., Johnson K. J., Swartz R. D., Varani J., Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Investigative Radiology 2010 45 1 42 48 2-s2.0-74049128372 10.1097/RLI.0b013e3181bf95eb
59. Piera-Velazquez S., Louneva N., Fertala J., Wermuth P. J., Del Galdo F., Jimenez S. A., Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases 2010 69 11 2017 2023 2-s2.0-77957354309 10.1136/ard.2009.127761
60. Gambichler T., Kreuter A., Skrygan M., Burkert B., Altmeyer P., Schieren G., Decorin is significantly overexpressed in nephrogenic systemic fibrosis. American Journal of Clinical Pathology 2009 132 1 139 143 2-s2.0-67650473208 10.1309/AJCPGB55YDURJXZC
61. Kuro-O M., Phosphate and klotho. Kidney International 2011 79 121 S20 S23 2-s2.0-79953268951 10.1038/ki.2011.26
62. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. I., Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Molecular Endocrinology 2003 17 12 2393 2403 2-s2.0-0346849707 10.1210/me.2003-0048 (Pubitemid 37542205)
63. Mathai S. K., Gulati M., Peng X., Russell T. R., Shaw A. C., Rubinowitz A. N., Murray L. A., Siner J. M., Antin-Ozerkis D. E., Montgomery R. R., Reilkoff R. A., Bucala R. J., Herzog E. L., Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation 2010 90 6 812 823 2-s2.0-77954602335 10.1038/labinvest.2010.73
64. Doi S., Zou Y., Togao O., Pastor J. V., John G. B., Wang L., Shiizaki K., Gotschall R., Schiavi S., Yorioka N., Takahashi M., Boothman D. A., Kuro-o M., Klotho inhibits transforming growth factor- β 1 (TGF- β 1) signaling and suppresses renal fibrosis and cancer metastasis in mice. Journal of Biological Chemistry 2011 286 10 8655 8665 2-s2.0-79953138206 10.1074/jbc.M110.174037
65. Cheng S., Abramova L., Saab G., Turabelidze G., Patel P., Arduino M., Hess T., Kallen A., Jhung M., Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Mo, USA, 2002-2006. Morbidity and Mortality Weekly Report 2007 56 7 137 141 2-s2.0-33847248060
66. Mendoza F. A., Artlett C. M., Sandorfi N., Latinis K., Piera-Velazquez S., Jimenez S. A., Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Seminars in Arthritis and Rheumatism 2006 35 4 238 249 2-s2.0-31844452583 10.1016/j.semarthrit.2005.08.002 (Pubitemid 43185214)
67. Khurana A., Runge V. M., Narayanan M., Greene J. F., Nickel A. E., Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Investigative Radiology 2007 42 2 139 145 2-s2.0-33846223894 10.1097/01.rli.0000253505.88945.d5 (Pubitemid 46104895)
68. Naylor E., Hu S., Robinson-Bostom L., Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. Journal of the American Academy of Dermatology 2008 58 1 149 150 2-s2.0-37349092675 10.1016/j.jaad.2007.07.018 (Pubitemid 350298139)
69. Kribben A., Witzke O., Hillen U., Barkhausen J., Daul A. E., Erbel R., Nephrogenic systemic fibrosis. Pathogenesis, diagnosis, and therapy. Journal of the American College of Cardiology 2009 53 18 1621 1628 2-s2.0-62349129232 10.1016/j.jacc.2008.12.061
70. Swaminathan S., Leung N., Nephrogenic fibrosing dermopathy: lessons from the past. International Journal of Dermatology 2006 45 6 639 641 2-s2.0-33745942538 10.1111/j.1365-4632.2006.02837.x (Pubitemid 44056659)
71. Grobner T., Prischl F. C., NSF: what we know and what we need to know: patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Seminars in Dialysis 2008 21 135 139
72. Perazella M. A., Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Current Opinion in Nephrology and Hypertension 2009 18 6 519 525 2-s2.0-73349130444 10.1097/MNH.0b013e3283309660
73. Introcaso C. E., Hivnor C., Cowper S., Werth V. P., Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. International Journal of Dermatology 2007 46 5 447 452 2-s2.0-34248182038 10.1111/j.1365-4632.2007.03301.x (Pubitemid 46711420)
74. Daram S. R., Cortese C. M., Bastani B., Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. American Journal of Kidney Diseases 2005 46 4 754 759 2-s2.0-25644446206 10.1053/j.ajkd.2005.06.024 (Pubitemid 41383955)
75. Perazella M. A., Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clinical Journal of the American Society of Nephrology 2007 2 2 200 202 2-s2.0-34347340885 10.2215/CJN.00030107
76. Golding L. P., Provenzale J. M., Nephrogenic systemic fibrosis: possible association with a predisposing infection. American Journal of Roentgenology 2008 190 4 1069 1075 2-s2.0-42449129986 10.2214/AJR.07.2884 (Pubitemid 351571527)
77. Lauenstein T. C., Salman K., Morreira R., Tata S., Tudorascu D., Baramidze G., Singh-Parker S., Martin D. R., Nephrogenic systemic fibrosis: center case review. Journal of Magnetic Resonance Imaging 2007 26 5 1198 1203 2-s2.0-35848946598 10.1002/jmri.21136 (Pubitemid 350058286)
78. Boyd A. S., Zic J. A., Abraham J. L., Gadolinium deposition in nephrogenic fibrosing dermopathy. Journal of the American Academy of Dermatology 2007 56 1 27 30 2-s2.0-33845702376 10.1016/j.jaad.2006.10.048 (Pubitemid 44969309)
79. Mazhar S. M., Shiehmorteza M., Kohl C. A., Middleton M. S., Sirlin C. B., Nephrogenic systemic fibrosis in liver disease: a systematic review. Journal of Magnetic Resonance Imaging 2009 30 6 1313 1322 2-s2.0-73649142429 10.1002/jmri.21983
80. Chow D. S., Bahrami S., Raman S. S., Rotchel S., Sayre J. W., Busuttil R. W., Lu D. S., Risk of nephrogenic systemic fibrosis in liver transplantation patients. American Journal of Roentgenology 2011 197 658 662
81. Koreishi A. F., Nazarian R. M., Saenz A. J., Klepeis V. E., McDonald A. G., Farris A. B., Colvin R. B., Duncan L. M., Mandal R. V., Kay J., Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Archives of Pathology & Laboratory Medicine 2009 133 1943 1948
82. Brunner S., Zaruba M. M., Huber B., David R., Vallaster M., Assmann G., Mueller-Hoecker J., Franz W. M., Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Experimental Hematology 2008 36 9 1157 1166 2-s2.0-49349084463 10.1016/j.exphem.2008.03.014
83. Lomonte C., Derosa C., Vernaglione L., Casucci F., Losurdo N., Libutti P., Teutonico A., Basile C., Serum parathyroid hormone and phosphate influence the levels of circulating CD34+ cells in uremia. Journal of Nephrology 2010 23 6 693 698 2-s2.0-78549241293
84. Kallen A. J., Jhung M. A., Cheng S., Hess T., Turabelidze G., Abramova L., Arduino M., Guarner J., Pollack B., Saab G., Patel P. R., Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. American Journal of Kidney Diseases 2008 51 6 966 975 2-s2.0-44049099289 10.1053/j.ajkd.2007.12.036 (Pubitemid 351711602)
85. Aggarwal A., Complications of nephrogenic systemic fibrosis following repeated exposure to gadolinium in a man with hypothyroidism: a case report. Journal of Medical Case Reports 2011 5 566
86. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M. B., Heaf J. G., Thomsen H. S., Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Journal of the American Society of Nephrology 2006 17 9 2359 2362 2-s2.0-33748049106 10.1681/ASN.2006060601 (Pubitemid 44300951)
87. Sadowski E. A., Bennett L. K., Chan M. R., Wentland A. L., Garrett A. L., Garrett R. W., Djamali A., Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007 243 1 148 157 2-s2.0-34147193807 10.1148/radiol.2431062144 (Pubitemid 46579705)
88. Idée J. M., Port M., Medina C., Lancelot E., Fayoux E., Ballet S., Corot C., Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008 248 2-3 77 88 2-s2.0-44149114715 10.1016/j.tox.2008.03.012
89. Swaminathan S., Horn T. D., Pellowski D., Abul-Ezz S., Bornhorst J. A., Viswamitra S., Shah S. V., Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. New England Journal of Medicine 2007 357 720 722 (Pubitemid 47267261)
90. Panesar M., Boateng F., Patel S. S., Masood S. F., Mahajan P., Patel N., Murray B., Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients? Hemodialysis International 2010 14 3 289 294 2-s2.0-77955022027 10.1111/j.1542-4758.2010.00456.x
91. Hope T. A., High W. A., LeBoit P. E., Chaopathomkul B., Rogut V. S., Herfkens R. J., Brasch R. C., Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009 253 2 390 398 2-s2.0-77950101549 10.1148/radiol.2532090580
92. High W. A., Ayers R. A., Cowper S. E., Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2007 56 4 710 712 2-s2.0-33947140510 10.1016/j.jaad.2007.01.022 (Pubitemid 46400200)
93. Miyamoto J., Tanikawa A., Igarashi A., Hataya H., Kobayashi K., Ikegami M., Sotome A., Nagai Y., Kameyama K., Ishiko A., Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. American Journal of Dermatopathology 2011 33 3 271 276 2-s2.0-79955521877 10.1097/DAD.0b013e3181f63eb1
94. Haroon Z. A., Amin K., Jiang X., Arcasoy M. O., A novel role for erythropoietin during fibrin-induced wound-healing response. American Journal of Pathology 2003 163 3 993 1000 2-s2.0-0041423388 (Pubitemid 37040135)
95. Yerram P., Saab G., Karuparthi P. R., Hayden M. R., Khanna R., Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clinical Journal of the American Society of Nephrology 2007 2 2 258 263 2-s2.0-34249818373 10.2215/CJN.03250906
96. DiCarlo J. B., Gupta E. A., Solomon A. R., A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. Journal of the American Academy of Dermatology 2006 54 5 914 916 2-s2.0-33646087915 10.1016/j.jaad.2006.01.023
97. Saab G., Cheng S., Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodialysis International 2007 11 3, supplement S2 S6 2-s2.0-34848901072 10.1111/j.1542-4758.2007.00222.x (Pubitemid 47491284)
98. Swaminathan S., Ahmed I., McCarthy J. T., Albright R. C., Pittelkow M. R., Caplice N. M., Griffin M. D., Leung N., Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Annals of Internal Medicine 2006 145 3 234 235 2-s2.0-33746823044 (Pubitemid 46780577)
99. Wahba I. M., Simpson E. L., White K., Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. American Journal of Transplantation 2007 7 10 2425 2432 2-s2.0-34548358966 10.1111/j.1600-6143.2007.01941.x (Pubitemid 47347864)
100. Khurana A., Greene J. F., High W. A., Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. Journal of the American Academy of Dermatology 2008 59 2 218 224 2-s2.0-47049097493 10.1016/j.jaad.2008.04.010
101. Frenzel T., Lengsfeld P., Schirmer H., Hütter J., Weinmann H. J., Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Investigative Radiology 2008 43 12 817 828 2-s2.0-59649103411 10.1097/RLI.0b013e3181852171
102. Fretellier N., Idée J., Bruneval P., Hyperphosphataemia sensitizes renally-impaired rats to profibrotic effects of gadodiamide. British Journal of Pharmacology 2012 165 2 1151 1162
103. Abraham J. L., Thakral C., Skov L., Rossen K., Marckmann P., Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. British Journal of Dermatology 2008 158 2 273 280 2-s2.0-38349103948 10.1111/j.1365-2133.2007. 08335.x
104. Peak A. S., Sheller A., Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Annals of Pharmacotherapy 2007 41 9 1481 1485 2-s2.0-34548156931 10.1345/aph.1K295 (Pubitemid 47311368)
105. Marckmann P., Skov L., Rossen K., Heaf J. G., Thomsen H. S., Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrology Dialysis Transplantation 2007 22 11 3174 3178 2-s2.0-36749027741 10.1093/ndt/gfm261 (Pubitemid 350202540)
106. Boyd A. S., Sanyal S., Abraham J. L., Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? Journal of the American Academy of Dermatology 2010 62 2 337 342 2-s2.0-73649106155 10.1016/j.jaad.2009.04.010